Earnings Releases·Oct 28, 2026, 4:08 PM ET

CONMED Corporation — Third Quarter 2026 Earnings Summary

Net sales declined 0.7% YoY to $335.6 million, while organic constant currency sales rose 6.7%; GAAP diluted EPS surged 613.7% to $0.66, whereas adjusted diluted EPS fell 3.2% to $1.04.
Full-year 2026 adjusted diluted EPS guidance was raised to $4.54–$4.61 (from $4.48–$4.60), with net sales guidance narrowed to $1,360–$1,366 million.
The company completed strategic exits of GI product offerings and sharpened its focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair markets.
Orthopedic Surgery sales grew 7.7% to $148.8 million, driven by key platforms including AirSeal, which recently received indication for use with Intuitive's da Vinci 5 platform.